This will be my last post of the year, so I wanted to do a quick summary of Scaling Biotech in 2024.
I have to say---my approach to usage of LLMs has evolved, too. We're now using them for the most trivial purpose (the one you mentioned in the other newsletter's wrap-up post) and are experimenting with a few more use cases.
I have to say---my approach to usage of LLMs has evolved, too. We're now using them for the most trivial purpose (the one you mentioned in the other newsletter's wrap-up post) and are experimenting with a few more use cases.